IRIS UniCatt

Cassano, Alessandra
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.367
EU - Europa 4.251
AS - Asia 3.781
SA - Sud America 701
Continente sconosciuto - Info sul continente non disponibili 190
AF - Africa 117
OC - Oceania 7
Totale 15.414
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.163
SG - Singapore 1.761
DE - Germania 1.483
CN - Cina 729
SE - Svezia 638
BR - Brasile 552
IT - Italia 533
VN - Vietnam 423
PL - Polonia 327
FR - Francia 291
GB - Regno Unito 235
IN - India 178
IE - Irlanda 144
UA - Ucraina 144
BD - Bangladesh 139
FI - Finlandia 120
ID - Indonesia 110
CA - Canada 98
JP - Giappone 84
RU - Federazione Russa 78
HK - Hong Kong 77
TR - Turchia 62
AR - Argentina 57
MX - Messico 55
BE - Belgio 41
NL - Olanda 40
CI - Costa d'Avorio 37
IQ - Iraq 37
ZA - Sudafrica 36
ES - Italia 34
AT - Austria 32
IR - Iran 25
EC - Ecuador 24
CO - Colombia 19
SA - Arabia Saudita 19
PK - Pakistan 18
CZ - Repubblica Ceca 17
LT - Lituania 17
VE - Venezuela 16
KR - Corea 14
MA - Marocco 13
AE - Emirati Arabi Uniti 12
UZ - Uzbekistan 12
CH - Svizzera 11
CL - Cile 11
PY - Paraguay 10
RO - Romania 10
TT - Trinidad e Tobago 9
CR - Costa Rica 8
JM - Giamaica 8
LU - Lussemburgo 8
PH - Filippine 8
JO - Giordania 7
MY - Malesia 7
NP - Nepal 7
PT - Portogallo 7
AL - Albania 6
AZ - Azerbaigian 6
IL - Israele 6
MD - Moldavia 6
OM - Oman 6
PE - Perù 6
AU - Australia 5
BG - Bulgaria 5
KE - Kenya 5
LV - Lettonia 5
SV - El Salvador 5
EG - Egitto 4
GT - Guatemala 4
LB - Libano 4
NI - Nicaragua 4
NO - Norvegia 4
RS - Serbia 4
SN - Senegal 4
TN - Tunisia 4
BB - Barbados 3
BO - Bolivia 3
ET - Etiopia 3
EU - Europa 3
GE - Georgia 3
HN - Honduras 3
KG - Kirghizistan 3
KZ - Kazakistan 3
LK - Sri Lanka 3
PA - Panama 3
PS - Palestinian Territory 3
QA - Qatar 3
TH - Thailandia 3
UY - Uruguay 3
AO - Angola 2
CG - Congo 2
CM - Camerun 2
DK - Danimarca 2
HU - Ungheria 2
IS - Islanda 2
KW - Kuwait 2
ML - Mali 2
NZ - Nuova Zelanda 2
SY - Repubblica araba siriana 2
A2 - ???statistics.table.value.countryCode.A2??? 1
Totale 15.211
Salva come PNG Salva come JPEG
Città #
Singapore 1.030
Chandler 796
Ashburn 667
San Jose 534
Warsaw 308
New York 178
Fairfield 171
Beijing 156
Council Bluffs 142
Dublin 142
Los Angeles 139
Ho Chi Minh City 128
Wilmington 125
San Mateo 120
Ann Arbor 116
Jacksonville 111
Hanoi 107
Houston 97
Lauterbourg 93
Woodbridge 93
Nürnberg 91
Jakarta 88
Chicago 84
Nanjing 83
Rome 79
Seattle 77
Boston 75
Tokyo 75
Dallas 71
Frankfurt am Main 68
Hong Kong 68
Cattolica 66
Milan 63
Munich 63
Helsinki 62
Cambridge 58
Princeton 58
The Dalles 53
Dearborn 52
Santa Clara 50
São Paulo 50
Hyderabad 48
Redmond 48
Moscow 45
Hefei 42
London 42
Marseille 41
Brussels 40
Abidjan 37
Izmir 36
Boardman 34
Orem 34
Denver 33
Nanchang 32
Phoenix 32
Toronto 31
Shanghai 30
Redwood City 28
Buffalo 27
Bremen 26
Brooklyn 26
Lawrence 25
Paris 25
Matera 24
Atlanta 23
Falls Church 23
Montreal 21
Augusta 20
Johannesburg 19
Leawood 19
Norwalk 19
Nuremberg 19
Mountain View 18
Rio de Janeiro 18
Vienna 18
Haiphong 17
Poplar 17
San Francisco 17
Amsterdam 16
Manchester 16
Chennai 15
Düsseldorf 15
Hebei 15
Philadelphia 15
Hangzhou 14
Kraków 14
Lancaster 14
Lappeenranta 14
Stockholm 14
Agrolândia 13
Dong Ket 13
Mexico City 13
Mumbai 13
Newark 13
Brasília 12
Changsha 12
Da Nang 12
Guangzhou 12
Kent 12
Kish 12
Totale 8.040
Salva come PNG Salva come JPEG
Nome #
Chance of cure following liver resection for initially unresectable colorectal metastases: analysis of actual 5-year survival 420
Pembrolizumab as first-line treatment for metastatic uveal melanoma 362
Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy 360
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real- world experience 349
C-myc expression is a possible keystone in the colorectal cancer resistance to egfr inhibitors 337
Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? 311
Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents 264
Complete Metabolic Response with Recanalization of Portal Vein Tumor Thrombosis after Sunitinib in a Patient with Advanced Hepatocellular Carcinoma 241
KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients 241
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience 239
Association of IL-8 and eNOS polymorphisms with clinical outcomes in bevacizumab-treated breast cancer patients: an exploratory analysis 234
[Gastrointestinal stromal tumors] 225
c-MYC Expression Is a Possible Keystone in the Colorectal Cancer Resistance to EGFR Inhibitors. 223
Gastrointestinal stromal tumors (GISTs) and second malignancies A novel sentinel tumor? A monoinstitutional, STROBE-compliant observational analysis 211
Thymoma in patients with MG: characteristics and long-term outcome 207
Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases 205
Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo 201
PDGFRA-mutant syndrome 194
Liver metastasectomy for metastatic breast cancer patients: A single institution retrospective analysis 194
Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients 190
Trastuzumab-induced corneal ulceration: successful no-drug treatment of a "blind" side effect in a case report 188
Standardizing percutaneous Microwave Ablation in the treatment of Lung Tumors: a prospective multicenter trial (MALT study) 186
“Triple positive” early breast cancer: an observational multicenter retrospective analysis of outcome 182
Case of Rectal GI Stromal Tumor Demonstrating that KIT and PDGFRA Mutations Are Not Always Mutually Exclusive 180
Are TKIs favourable for the elderly with non-small-cell lung cancer? 174
Is surgery mandatory in locally advanced gastrointestinal stromal tumors after imatinib? A case report and literature review. 173
HepatoCATT Study Group for the Multidisciplinary Management of HCC. Interventional oncology treatments for unresectable early stage HCC in patients with a high risk for intraprocedural bleeding: Is a single-step combined therapy safe and feasible? 173
Liver metastasectomy for metastatic breast cancer patients: A single institution retrospective analysis 172
KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study 169
Osteoradionecrosis incidence in pre‐radiation teeth extractions: A prospective study 168
Conversion Chemotherapy for Technically Unresectable Colorectal Liver Metastases 166
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence 162
Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): A randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX 161
Neoadjuvant chemotherapy for patients with muscle-invasive urothelial bladder cancer candidates for curative surgery: A prospective clinical trial based on cisplatin feasibility 159
The impact of multidisciplinary team management on outcome of hepatic resection in liver-limited colorectal metastases 158
Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity 157
Let‐7a‐5p, mir‐100‐5p, mir‐101‐3p, and mir‐199a‐3p hyperexpression as potential predictive biomarkers in early breast cancer patients 157
ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas 156
Palbociclib plus fulvestrant or everolimus plus exemestane for pretreated advanced breast cancer with lobular histotype in er+/her2− patients: A propensity score-matched analysis of a multicenter retrospective patient series 155
Transradial versus Transfemoral Access for Hepatic Chemoembolization: Intrapatient Prospective Single-Center Study 154
"Triple positive" early breast cancer: An observational multicenter retrospective analysis of outcome 149
Maintenance hormonal and chemotherapy treatment in metastatic breast cancer: a systematic review. 149
RUNX3 as a Potential Predictor of Metastasis in Human Pancreatic Cancer 149
Advanced colon cancer: staging and prognosis by CEA test 148
First-line treatment of advanced biliary ducts carcinoma: A randomized phase II study evaluating 5-FU/LV Plus oxaliplatin (Folfox 4) versus 5-FU/LV (de gramont regimen) 148
Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: A single institution phase II study 146
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation 146
Interventional oncology treatment for unresecable early stage HCC in patient with high risk for intraprocedural bleeding: is a single step combined therapy safe and feasible? 145
Monoinstitutional real world experience in management of vinflunine as second line therapy for transitional cell carcinoma of the urothelium 144
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 143
Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents 142
Novel epigenetic eight-gene signature predictive of poor prognosis and msi-like phenotype in human metastatic colorectal carcinomas 142
Mutational status of plasma exosomal KRAS predicts outcome in patients with metastatic colorectal cancer 142
[Gastrointestinal stromal tumors] 138
ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis. 138
From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer? 136
Immunological backbone of uveal melanoma: Is there a rationale for immunotherapy? 136
Successful "on- demand" plerixafor for autologous peripheral blood stem-cells transplantation for relapsed/refractory germ cell tumors. 135
eComment. Iterative metastasectomy for recurrent pulmonary disease from colorectal cancer: A challenging issue 134
Mutational status of plasma exosomal KRAS predicts outcome in patients with metastatic colorectal cancer 134
Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis. 133
Clinical outcomes of teeth adjacent to the site of mandibulotomy or mandibulectomy in patients with head and neck cancer: results from a multidisciplinary mono-institutional head and neck tumor board 133
Divergent gastrointestinal stromal tumors in syndromic settings 129
Cdk4/6 inhibitor treatments in patients with hormone receptor positive, her2 negative advanced breast cancer: Potential molecular mechanisms, clinical implications and future perspectives 128
In reply to the letter to the editor regarding "Clinical outcomes of teeth adjacent to the site of mandibulotomy or mandibulectomy in patients with head and neck cancer: results from a multidisciplinary mono-institutional head and neck tumor board" 128
Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer 127
Cardiac metastasis from renal cell carcinoma successfully treated with pazopanib: impact of TKIs' antiangiogenic activity. 124
Targeted Therapy in Advanced Gastric Carcinoma:the Future is Beginning 124
Operator learning curve for transradial liver cancer embolization: Implications for the initiation of a transradial access program 122
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 118
Interventional oncology treatments for unresectable early stage HCC in patients with a high risk for intraprocedural bleeding: Is a single-step combined therapy safe and feasible? 115
Are Markers of Systemic Inflammation Good Prognostic Indicators in Colorectal Cancer? 113
Long term follow up of a pilot study with neoadjuvant EEP ( epidoxorubicin, Etoposide and Cisplatin) in gastric cancer. 112
Lung adenocarcinoma presenting as a solitary gingival metastasis: a case report 111
Authors' reply “Osteoradionecrosis incidence in preradiation teeth extractions: A prospective study” 110
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study 110
Primary cardiac synovial sarcoma: A review correlating outcomes with surgery and adjuvant therapy 110
Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study 109
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer 109
Percutaneous radiofrequency ablation using internally cooled wet electrodes for the treatment of patients with lung tumors 107
Poor efficacy of palbociclib in second-line treatment of metastatic lobular breast cancer in a case series: Use before or never more? 107
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 107
Oral Health Status in Patients with Head and Neck Cancer before Radiotherapy: Baseline Description of an Observational Prospective Study 107
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 106
Long-term follow-up of a pilot phase II study with neoadjuvant epidoxorubicin, etoposide and cisplatin in gastric cancer 105
Cryoablation in Locoregional Management of Complex Unresectable Chest Neoplasms 102
Poor efficacy of palbociclib in second-line treatment of metastatic lobular breast cancer in a case series: Use before or never more? 98
Trans-Arterial Chemoembolization with Irinotecan-Loaded Drug-Eluting Beads (DEBIRI) and Capecitabine in Refractory Liver Prevalent Colorectal Metastases: A Phase II Single-Center Study 95
Treatment of locally advanced gastric cancer (LAGC): Back to lauren’s classification in pan– cancer analysis era? 95
Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse 92
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab 92
Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer. 86
Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study) 82
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting 79
Targeted therapy in advanced gastric carcinoma: The future is beginning 78
Triple positive breast cancer: A distinct subtype? 77
Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors 74
Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line 58
Totale 15.414
Salva come PNG Salva come JPEG
Categoria #
all - tutte 60.348
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.348
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022828 0 0 0 111 60 40 22 149 52 59 132 203
2022/20232.031 272 285 158 348 110 240 98 192 197 38 66 27
2023/2024794 32 223 31 32 30 121 54 39 13 32 86 101
2024/20251.802 37 65 139 98 152 66 48 100 237 223 330 307
2025/20265.314 685 132 275 685 989 290 965 244 373 286 178 212
2026/2027913 141 152 358 262 0 0 0 0 0 0 0 0
Totale 15.414